Post-FDA Approval: Preliminary treatment data collection
WHO
Revance is a biotechnology company setting the new standard in healthcare by elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings. Revance is an innovation leader in aesthetics and therapeutics.
Data collection from pre-selected HCPs for a new treatment
The intention is to collect treatment data including before & after photos, injection sites, injection volume, videos, and accompanying patient satisfaction.
WHAT
Hand selected patient population from participating HCPs
Participating providers are hand selected for being part of this cohort. These providers are compensated for the specified data collected per patient per treatment. Sequential data collection required for multiple visits, validated in the UI:
– Patient Progression Status
– Each patient needed 4 separate stages to be complete to credit HCP for compensation
– Adding of new patients to the program
– Patient completion counter for maximum compensated participants
Consent, Identifiable data & Treatment history
Every patient is required to opt-in to the program once they are added via QR-code to a programmatic DocuSign. Past treatment data is collected in a user friendly wizard. Patient phone numbers are collected for post-treatment surveys.
Treatment areas
in detail
Volumetric recording of units to injection sites with pin placement on a representative face
Integration with Dropbox for generated images with corresponding X,Y facial coordinates and volumes
Easy to use pin dropping, iPad enabled for touch
Patient
Before & Afters
Standard photo collection for before & after (resting, max frown, max lift and facial video)
Immediate post-injection photo specified for adverse reaction and injection site photo verification
Locked follow-up photo collection requiring a returning visit based on a treatment timeline
SMS triggered surveys
Gauging patient satisfaction at timed intervals governed by the treatment effectiveness timeline
Automatic enrollment in PrevU on patients coming from Prelude
Public enrollment in PrevU from patients
The results
Prelude Program Success
Exceptional data quality as UI validation and systematic patient workflows made new patient ingestion easy and fast.
Injection sites and volume validated by medical affairs as correct procedure.
Validation of treatment techniques for a new drug that requires different reconstitution and procedure than the common neuromodulator.
- FAQ
What is the Revance Prelude program?
The Revance Prelude program is a data collection platform developed for Revance by Kingsmen Digital Ventures, designed to capture post-FDA treatment data from HCPs, including before-and-after photos, injection sites, volumes, and patient satisfaction surveys.
How did Kingsmen build Prelude for Revance?
Kingsmen Digital Ventures partnered with Revance to design and develop Prelude, incorporating iPad-enabled pin dropping, QR code patient enrollment, DocuSign consent, and SMS surveys to enable seamless, real-time data capture.
What are the benefits of Prelude?
Through a platform built by Kingsmen Digital Ventures for Revance, HCPs receive compensation for each validated patient, while Revance gains high-quality injection data and valuable insights to validate treatment techniques for its neuromodulator.
How does Prelude help Revance succeed?
By collaborating with Kingsmen Digital Ventures, Revance leverages Prelude to achieve exceptional data quality and workflow efficiency, reinforcing its leadership in aesthetic innovation following FDA approval.